SCHEDULE 13G/A: BlackRock Discloses 12.8% Passive Stake in TG Therapeutics

BlackRock, Inc. has filed an updated Schedule 13G, revealing a 12.8% beneficial ownership stake in TG Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 20,134,882 shares of TG Therapeutics, Inc. Common Stock.
• This ownership represents 12.8% of the total outstanding shares of TG Therapeutics, Inc.
• BlackRock holds sole voting power over 19,967,724 shares and sole dispositive power over 20,134,882 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• One of BlackRock's entities, iShares Core S&P Small-Cap ETF, holds more than 5% of the total outstanding common stock of TG Therapeutics, Inc.
• Another entity, BlackRock Fund Advisors, also beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a passive filing, the disclosure of a significant stake by a major institutional investor like BlackRock can be interpreted as a vote of confidence in the company, potentially signaling stability and attracting further investor interest.

Positives

• The significant stake held by a major institutional investor like BlackRock may signal confidence in TG Therapeutics' long-term prospects.
• Increased institutional ownership can sometimes lead to greater market stability and liquidity for the stock.

Risks

• The filing is a passive investment disclosure and does not indicate any active engagement or strategic partnership with TG Therapeutics' management, limiting direct influence on company direction.
• The value of BlackRock's investment is subject to market fluctuations and the performance of TG Therapeutics' stock.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding TG Therapeutics' future financial performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Statement from BlackRock, Inc. as the reporting person)

Industry Context

BlackRock, as one of the world's largest asset managers, routinely files Schedule 13G reports to disclose its passive ownership stakes in publicly traded companies. This filing indicates BlackRock's continued investment activity across various sectors, including biotechnology, aligning with its broad market exposure strategies through its various funds and managed portfolios.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by BlackRock may enhance investor confidence and potentially influence market perception of TG Therapeutics' stock.
• Company Management: Awareness of a large passive institutional holder may influence strategic decisions, though BlackRock's stated intent is not to influence control.

Key Dates

Keywords

BlackRock, TG Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, Investment Management, Pharmaceuticals, Biotechnology